These observations suggest that theability to upregulate MCL-1 and/or BCL-XL in response to inhibition ofBCL-2 is shared amongst AML cells, irrespective of their levels of baselinesensitivity to ABT-199. The gene discussed is BCL2L1; the disease is acute myeloid leukemia.